Want to join the conversation?
In 1Q16, $VRTX plans to commence a clinical trial for KALYDECO (ivacaftor) in patients with CF less than two years of age to evaluate the effect of ivacaftor on markers of CF disease in young children. $VRTX has submitted a supplemental New Drug Application, sNDA, for KALYDECO and a target review date for the sNDA is set for Feb. 6, 2016.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.